<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05097872</url>
  </required_header>
  <id_info>
    <org_study_id>S65495</org_study_id>
    <nct_id>NCT05097872</nct_id>
  </id_info>
  <brief_title>ConfocAl endomicroSCopy bAsed Diet Trial in IBS</brief_title>
  <acronym>CASCADE</acronym>
  <official_title>Targeted Elimination Diet in IBS Patients Following Identification of Trigger Nutrients Using Confocal Laser Endomicroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After a thorough baseline evaluation, IBS patients will be exposed to nutrients while&#xD;
      undergoing confocal laser endomicroscopy (CLE). Patients presenting an acute mucosal reaction&#xD;
      upon nutrient exposure will be instructed to exclude their respective trigger nutrient or a&#xD;
      nutrient without mucosal reaction (=sham diet) from their diet for 4 weeks in a randomized,&#xD;
      blinded crossover fashion.&#xD;
&#xD;
      The aim of the trial is to assess the symptomatic response to the targeted diet and further&#xD;
      elucidate mechanisms underlying the acute mucosal reactions observed in CLE upon nutrient&#xD;
      exposure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder rates in targeted diet vs sham diet</measure>
    <time_frame>After 4 weeks of dietary intervention</time_frame>
    <description>Response defined by an improvement of minimum 50 points in the IBS-SSS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline permeability measures between groups</measure>
    <time_frame>At baseline</time_frame>
    <description>Differences in baseline permeability measures between CLE positive and negative patients and healthy volunteers using Ussing chambers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of permeability measures between dietary interventions</measure>
    <time_frame>Baseline and end of respective dietary intervention</time_frame>
    <description>Differences in permeability measures between dietary interventions (i.e. verum, sham, wheat and soy) during the dietary interventions using urinary Lactulose/Mannitol/Sucralose ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline mucosal immune cell composition between groups</measure>
    <time_frame>Baseline</time_frame>
    <description>Differences in baseline mucosal mast-cell and eosinophil counts between CLE positive and negative patients</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Real diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diet excluding the trigger nutrient identified by an acute mucosal reaction in CLE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham diet</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Diet excluding a sham nutrient without acute mucosal reaction in CLE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wheat exclusion diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In patients without identified trigger nutrient (i.e. no acute mucosal reaction to any nutrient), wheat will be excluded as an empirical diet in crossover fashion with soy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soy exclusion diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In patients without identified trigger nutrient (i.e. no acute mucosal reaction to any nutrient), wheat will be excluded as an empirical diet in crossover fashion with soy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>Diet excluding either trigger and sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)</description>
    <arm_group_label>Real diet</arm_group_label>
    <arm_group_label>Sham diet</arm_group_label>
    <arm_group_label>Soy exclusion diet</arm_group_label>
    <arm_group_label>Wheat exclusion diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-70 y/o (70 years included)&#xD;
&#xD;
          -  Male or female subjects&#xD;
&#xD;
          -  IBS-D and IBS-M (i.e. IBS-non-C) according to Rome IV criteria&#xD;
&#xD;
          -  Moderate to severe symptom severity as defined by the Irritable bowel syndrome&#xD;
             severity scoring system (IBS-SSS) (i.e. IBS-SSS &gt;175 points)&#xD;
&#xD;
          -  Provide written informed consent to participate in the study&#xD;
&#xD;
          -  Women of child-bearing potential agree to apply a highly effective method of birth&#xD;
             control during the entire duration of the trial. Highly effective birth control is&#xD;
             defined as those which result in a low failure rate (i.e., less than 1% per year) when&#xD;
             used constantly and correctly such as implants, injectables, combined oral&#xD;
             contraceptive method, or some intrauterine devices (IUDs), sexual abstinence, or&#xD;
             vasectomized partner. Women of non-childbearing potential may be included if&#xD;
             surgically sterile (tubal ligation or hysterectomy) or postmenopausal with at least 2&#xD;
             year without spontaneous menses.&#xD;
&#xD;
          -  Subjects who are capable to understand the study and the questionnaires, and to comply&#xD;
             with the study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Pregnant or breastfeeding women&#xD;
&#xD;
          -  History of major surgery of the gastrointestinal tract (cholecystectomy and&#xD;
             uncomplicated appendectomy are allowed)&#xD;
&#xD;
          -  Symptoms predominantly associated with functional dyspepsia or gastro-esophageal&#xD;
             reflux disease&#xD;
&#xD;
          -  Immunoglobuline E (IgE)-mediated food allergies identified by immunocap blood tests or&#xD;
             skin prick testing&#xD;
&#xD;
          -  Known underlying organic gastrointestinal disease&#xD;
&#xD;
          -  Current or recent use of NSAIDs, proton-pump inhibitors, systemic histamine-receptor&#xD;
             antagonists, mast cell stabilizers, corticosteroids, opioids (need to be stopped at&#xD;
             least 2 weeks). Use of antibiotics in the past 6 weeks.&#xD;
&#xD;
          -  Allergy to Fluorescein, Xylocaine or Propofol&#xD;
&#xD;
          -  Known celiac disease&#xD;
&#xD;
          -  Following a diet interfering with the study diet in opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lukas M Balsiger, MD</last_name>
    <phone>+32 16 37 70 90</phone>
    <email>lukasmichaja.balsiger@kuleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukas M Balsiger, MD</last_name>
      <phone>+32492447624</phone>
      <email>lukasmichaja.balsiger@kuleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

